Oct 21, 2023 · Sacituzumab govitecan is a Trop-2-directed antibody–drug conjugate distinguished by its high specificity and nanomolar affinity for Trop-2. The antibody binds to Trop-2 expressed on the surface of tumour cells, allowing for targeted delivery …

TROPiCS-02 is a phase 3 randomized study (NCT03901339) to confirm SG outcomes in HR+/HER2– advanced breast cancer. Methods: Adults with locally determined, HR+/HER2– unresectable locally advanced or MBC, ECOG performance status of 0 or 1, and 2-4 prior chemotherapy regimens for MBC were eligible; 1 prior therapy for MBC was allowed if ...

Oct 21, 2023 · Overall survival was significantly improved with sacituzumab govitecan versus chemotherapy (median 14·4 months [95% CI 13·0-15·7] vs 11·2 months [10·1-12·7]; hazard ratio [HR] 0·79, 95% CI 0·65-0·96; p=0·020); survival benefit was consistent across Trop-2 expression-level subgroups.

Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker.

Jul 27, 2024 · Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

May 31, 2023 · Conclusions: The final OS analysis of the TROPiCS-02 study confirms the clinically meaningful OS benefit of SG over single-agent CT in pts with pretreated, endocrine-resistant HR+/HER2–mBC. This improvement was independent of HER2-low status.

Jun 10, 2023 · The final overall survival (OS) analysis of the phase 3 TROPiCS-02 study (NCT03901339) demonstrated better outcomes with sacituzumab govitecan-hziy (Trodelvy) vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Jul 27, 2024 · Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial Lancet. 2024 Jul 27;404(10450):339. doi: 10.1016/S0140-6736(24)01048-1. Authors Kayo Harada 1 , Akihiko Ozaki 2 , Tetsuya Tanimoto 3 Affiliations 1 Ome Municipal ...

Jun 25, 2022 · Sacituzumab govitecan, an anti-Trop2 antibody-drug conjugate, is approved for patients with metastatic triple-negative breast cancer after at least two prior treatments (one or more for metastatic disease). The findings from TROPiCS-02 suggest the drug may be useful in women with hormone receptor–positive tumors as well.

Mar 30, 2020 · TROPiCS-02 is an ongoing Phase III, open-label, randomized, multicenter study of sacituzumab govitecan versus treatment of physician’s choice (TPC) in patients with HR+/HER2- metastatic breast canc...